Display options
Cite
Cécile P, Julien A, Andrea A, et al. UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment. Cells. 2018;7(11)doi: 10.3390/cells7110214.
Cécile, P., Julien, A., Andrea, A., Agnès, C., Cécile, C. G., Clara, T., Christiane, D., Lydie, C., Daniel, B., Marco, S., Didier, A., & Daniel, T. (2018). UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment. Cells, 7(11), . https://doi.org/10.3390/cells7110214
Cécile, Polge, et al. "UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment." Cells vol. 7,11 (2018). doi: https://doi.org/10.3390/cells7110214
Cécile P, Julien A, Andrea A, Agnès C, Cécile CG, Clara T, Christiane D, Lydie C, Daniel B, Marco S, Didier A, Daniel T. UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment. Cells. 2018 Nov 16;7(11). doi: 10.3390/cells7110214. PMID: 30453501; PMCID: PMC6262581.
Copy Download .nbib Format: NLM
Share it on

Cells. 2018 Nov 16;7(11). doi: 10.3390/cells7110214.

UBE2E1 Is Preferentially Expressed in the Cytoplasm of Slow-Twitch Fibers and Protects Skeletal Muscles from Exacerbated Atrophy upon Dexamethasone Treatment.

Cells

Polge Cécile, Aniort Julien, Armani Andrea, Claustre Agnès, Coudy-Gandilhon Cécile, Tournebize Clara, Deval Christiane, Combaret Lydie, Béchet Daniel, Sandri Marco, Attaix Didier, Taillandier Daniel

Affiliations

  1. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  2. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  3. Venetian Institute of Molecular Medicine, 35100 Padova, Italy. [email protected].
  4. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  5. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  6. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  7. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  8. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  9. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  10. Venetian Institute of Molecular Medicine, 35100 Padova, Italy. [email protected].
  11. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].
  12. INRA, UMR 1019, Human Nutrition Unit (UNH), 63122 St Genès Champanelle, France. [email protected].

PMID: 30453501 PMCID: PMC6262581 DOI: 10.3390/cells7110214

Abstract

Skeletal muscle mass is reduced during many diseases or physiological situations (disuse, aging), which results in decreased strength and increased mortality. Muscle mass is mainly controlled by the ubiquitin-proteasome system (UPS), involving hundreds of ubiquitinating enzymes (E2s and E3s) that target their dedicated substrates for subsequent degradation. We recently demonstrated that MuRF1, an E3 ubiquitin ligase known to bind to sarcomeric proteins (telethonin, α-actin, myosins) during catabolic situations, interacts with 5 different E2 enzymes and that these E2-MuRF1 couples are able to target telethonin, a small sarcomeric protein, for degradation. Amongst the E2s interacting with MuRF1, E2E1 was peculiar as the presence of the substrate was necessary for optimal MuRF1-E2E1 interaction. In this work, we focused on the putative role of E2E1 during skeletal muscle atrophy. We found that E2E1 expression was restricted to type I and type IIA muscle fibers and was not detectable in type IIB fibers. This strongly suggests that E2E1 targets are fiber-specific and may be strongly linked to the contractile and metabolic properties of the skeletal muscle. However, E2E1 knockdown was not sufficient for preserving the protein content in C2C12 myotubes subjected to a catabolic state (dexamethasone treatment), suggesting that E2E1 is not involved in the development of muscle atrophy. By contrast, E2E1 knockdown aggravated the atrophying process in both catabolic C2C12 myotubes and the Tibialis anterior muscle of mice, suggesting that E2E1 has a protective effect on muscle mass.

Keywords: E2 ubiquitin-conjugating enzymes; E3 ubiquitin ligases; MuRF1; UBE2E1; actin; atrophy; myosin heavy chain; skeletal muscle; ubiquitin-proteasome system

References

  1. FEBS J. 2018 Oct;285(20):3688-3694 - PubMed
  2. Mol Cells. 2018 Mar 31;41(3):168-178 - PubMed
  3. J Cell Physiol. 2002 Oct;193(1):120-31 - PubMed
  4. Essays Biochem. 2005;41:173-86 - PubMed
  5. Curr Opin Clin Nutr Metab Care. 2013 May;16(3):243-50 - PubMed
  6. Endocr Metab Immune Disord Drug Targets. 2012 Mar;12(1):95-103 - PubMed
  7. Oncol Lett. 2018 Sep;16(3):2949-2956 - PubMed
  8. J Cell Biochem. 2008 Oct 1;105(2):353-64 - PubMed
  9. J Biochem. 2005 Dec;138(6):711-9 - PubMed
  10. Endocrinology. 1998 Sep;139(9):4000-3 - PubMed
  11. Oncogene. 1999 Apr 15;18(15):2423-30 - PubMed
  12. Biochem J. 2011 Mar 1;434(2):309-19 - PubMed
  13. Front Physiol. 2015 Mar 10;6:59 - PubMed
  14. J Cell Biol. 2002 Apr 1;157(1):125-36 - PubMed
  15. Endocrinology. 2008 Feb;149(2):758-66 - PubMed
  16. Biochemistry. 2014 Jun 24;53(24):4004-14 - PubMed
  17. J Biol Chem. 2007 Feb 23;282(8):5302-9 - PubMed
  18. J Mol Biol. 2013 Nov 15;425(22):4099-111 - PubMed
  19. J Biol Chem. 2014 Aug 8;289(32):21909-25 - PubMed
  20. J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509 - PubMed
  21. FASEB J. 2010 Apr;24(4):981-93 - PubMed
  22. Nat Rev Clin Oncol. 2013 Feb;10(2):90-9 - PubMed
  23. J Biol Chem. 2010 Mar 19;285(12):8595-604 - PubMed
  24. Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18135-40 - PubMed
  25. Mol Syst Biol. 2009;5:295 - PubMed
  26. Int J Biochem Cell Biol. 2013 Oct;45(10):2121-9 - PubMed
  27. J Clin Invest. 2004 Jan;113(1):115-23 - PubMed
  28. Nat Struct Mol Biol. 2007 Oct;14(10):941-8 - PubMed
  29. Int J Biochem Cell Biol. 2016 Oct;79:505-516 - PubMed
  30. J Biol Chem. 2011 Dec 23;286(51):44104-15 - PubMed
  31. Chronobiol Int. 2014 May;31(4):506-14 - PubMed
  32. Int J Biochem Cell Biol. 2013 Oct;45(10):2191-9 - PubMed
  33. Science. 2001 Nov 23;294(5547):1704-8 - PubMed
  34. J Clin Invest. 2007 Sep;117(9):2486-95 - PubMed
  35. Int J Endocrinol. 2014;2014:983453 - PubMed
  36. FASEB J. 2004 Jan;18(1):39-51 - PubMed
  37. Genome Res. 2009 Oct;19(10):1905-11 - PubMed
  38. J Cell Biol. 2017 Mar 6;216(3):641-656 - PubMed
  39. J Physiol. 2011 Apr 15;589(Pt 8):2007-26 - PubMed
  40. J Gerontol A Biol Sci Med Sci. 2015 May;70(5):566-76 - PubMed
  41. J Cell Biol. 2004 Nov 22;167(4):649-59 - PubMed
  42. J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):129-145 - PubMed
  43. Nat Commun. 2015 Apr 10;6:6670 - PubMed
  44. Cell Metab. 2007 Nov;6(5):376-85 - PubMed
  45. PLoS One. 2015 Jun 08;10(6):e0128263 - PubMed
  46. Wiley Interdiscip Rev Dev Biol. 2016 Jul;5(4):518-34 - PubMed
  47. J Mol Biol. 2015 Jul 3;427(13):2290-304 - PubMed
  48. J Biol Chem. 2013 Jun 7;288(23):16975-85 - PubMed
  49. FASEB J. 2011 Nov;25(11):3790-802 - PubMed
  50. Circ Res. 2011 Sep 16;109(7):758-69 - PubMed
  51. Int J Biochem Cell Biol. 2016 Oct;79:488-493 - PubMed
  52. J Biol Chem. 2017 Feb 17;292(7):2893-2902 - PubMed
  53. Am J Physiol Endocrinol Metab. 2014 Sep 15;307(6):E469-84 - PubMed

Publication Types

Grant support